Healthcare
DocMorris AG(ZRSEF)
Live Price
Offline$10.24
+0.00% today
1Y Change
-3.17%
Window
Jun 23, 2025 β Jun 15, 2026
- Market Cap
- $340.00M
- Revenue Growth
- +10.6%
- EPS Growth
- +68.5%
- Dividend Yield
- 0.0%
Coverage: 246 bars Β· Jun 23, 2025 β Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
DocMorris AG (ZRSEF) is a Healthcare stock with a market cap of $340.00M and listed on OTC. The stock last traded around $10.24 and down 3.2% across the available one-year price window (Jun 23, 2025 β Jun 15, 2026). Baseline metrics include revenue growth of +10.6%, EPS growth of +68.5%, a dividend yield of 0.0%. What stands out right now is revenue +10.6%, EPS +68.5%, free cash flow -63.2% with operating margin -7.5% and ROIC -11.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.3. Stock Foundry combines ZRSEF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.6% vs +7.6% peer median
Operating Margin
Below sector median
-7.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on Mar 19, 2026 with revenue ahead of estimates by +91.8%.
The operating story is still moving forward
Revenue is running at +10.6% and EPS at +68.5%, with operating margin around -7.5%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 18, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 19, 2026 | β | +0.0% | +0.0% | +0.0% |
2025 Jun 30, 2025 | β | +0.0% | +0.0% | +0.0% |
2024 Dec 31, 2024 | β | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZRSEF
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
ZRSEF Max Drawdown
-3.17%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ZRSEF and SPY.
Company Overview
DocMorris AG
Other OTC
DocMorris AG operates e-commerce pharmacies and a wholesale business for medical and pharmaceutical products in Switzerland and internationally. The company offers consumer health, beauty, and personal care products, as well as medicines management services. It also operates stationary pharmacy shops. The company sells its products directly to physicians, online mail-order pharmacies, and private individuals under the Zur Rose, PromoFarma, TeleClinic, and DocMorris brands. The company was formerly known as Zur Rose AG and changed its name to Zur Rose Group AG in May 2015. The company was founded in 1993 and is headquartered in Frauenfeld, Switzerland.
- Leadership
- Walter Hess
- IPO Date
- Sep 28, 2018
- Employees
- 1.5k
- Street Address
- WalzmΓΌhlestrasse 60
- Mailing
- Frauenfeld, 8500
- Region
- Frauenfeld, CH
- Reporting Currency
- USD
- Investor Line
- 41 52 724 00 20
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 0.3
- Price/Book
- 0.9
Growth
- Revenue
- +10.6%
- EPS
- +68.5%
- Free Cash Flow
- -63.2%
Profitability
- Gross Margin
- 9.4%
- Operating Margin
- -7.5%
- Net Margin
- -12.0%
- ROE
- -30.2%
- ROIC
- -11.7%
Balance Sheet
- Debt/Equity
- 0.71
- Current Ratio
- 2.19
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.